1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
|
ID XP3OS
AC CVCL_3245
AS CVCL_F511
SY XP30S; GM04314
DR CLO; CLO_0019557
DR Coriell; GM04314
DR JCRB; JCRB0303
DR JCRB; KURB1002
DR JCRB; KURB1003
DR JCRB; KURB1004
RX PubMed=1372102;
ST Source(s): JCRB
ST Amelogenin: X
ST CSF1PO: 10,11
ST D13S317: 9,11
ST D16S539: 9,12
ST D5S818: 10,11
ST D7S820: 11,12
ST TH01: 7
ST TPOX: 8,11
ST vWA: 14,16
DI NCIt; C3965; Xeroderma pigmentosum, complementation group A
OX NCBI_TaxID=9606; ! Homo sapiens
SX Female
CA Finite cell line
//
ID 1-5c-4
AC CVCL_2260
SY Clone 1-5c-4; Clone 1-5c-4 WKD of Chang Conjunctiva; Wong-Kilbourne derivative of Chang conjunctiva; ChWK
DR CLO; CLO_0002500
DR CLO; CLO_0002501
DR CLDB; cl793
DR CLDB; cl794
DR CLDB; cl795
DR ATCC; CCL-20.2
DR BioSample; SAMN03151673
DR ECACC; 88021103
DR IZSLER; BS CL 93
DR KCLB; 10020.2
RX PubMed=566722;
RX PubMed=19630270;
RX PubMed=20143388;
WW http://iclac.org/wp-content/uploads/Cross-Contaminations-v7_2.pdf
CC Problematic cell line: Contaminated. Shown to be a HeLa derivative (PubMed 566722, PubMed 20143388).
CC Omics: Transcriptome analysis.
ST Source(s): ATCC; KCLB
ST Amelogenin: X
ST CSF1PO: 9,10
ST D13S317: 12,13.3
ST D16S539: 9,10
ST D3S1358: 15,18
ST D5S818: 11,12
ST D7S820: 8,12
ST FGA: 18,21
ST TH01: 7
ST TPOX: 8,12
ST vWA: 16,18
DI NCIt; C4029; Cervical adenocarcinoma
OX NCBI_TaxID=9606; ! Homo sapiens
HI CVCL_0030 ! HeLa
SX Female
CA Cancer cell line
//
|
